

PERSONAL INFORMATION

Mario Miguel Coelho da Silva Rosa

WORK EXPERIENCE

- September 2016- Present **Neurology Professor; Clinical Pharmacology Professor**
Faculdade de Medicina da Universidade de Lisboa (Portugal)
Clinical Pharmacology and Neurology Professor
Medical Ethics Lecturer
Clinical Pharmacology Investigator (Pharmacoepidemiology)
Coordinator of Medical Ethics - Master and PhD Programs at Universidade de Lisboa
Alternate Member of the Academic Council- Faculdade de Medicina da Universidade de Lisboa
2017, ongoing
- March 1998- Present **Clinical Pharmacology Expert**
INFARMED (Portugal)
Medicines HTA expert
CNS clinical pharmacology
Scientific Advice
Pharmacovigilance
Member of the Medicines Evaluation Commission
- January 1998- Present **Neurology Consultant**
Centro Hospitalar Universitário Lisboa Norte (Portugal)
Neurology Consultant at the University Hospital
Head of the Movement Disorders Outpatient Clinic
Past Member and Chair of the EVA (Decision on living donor for organ transplantation) Centro Hospitalar Lisboa Norte 2007-2020
Past (1990-2011) Principal and Co- Investigator CNS and Pain trials
- November 2011-April 2019 **Head of the Regional Pharmacovigilance Unit**
AIDFM - UFL (Portugal)
Head of the Greater Lisbon Regional Pharmacovigilance Unit (UFL)
- January 1991-December 1992 **Young practitioner**
Hospital Santa Maria (CHLN-CHULN) (Portugal)
- January 1990- 2016 **Neurology Lecturer; Clinical Pharmacology Lecturer**
Faculdade de Medicina da Universidade de Lisboa (Portugal)
Clinical Pharmacology and Neurology pre and post grad Lecturer
Clinical Pharmacology Investigator (Pharmacoepidemiology)

EDUCATION AND TRAINING

- October 1984-July 1990 **M.D.**
Faculdade de Medicina de Lisboa (Portugal)
Medical Degree
- September 2009-July 2016 **PhD**
Faculdade de Medicina da Universidade de Lisboa (Portugal)
Medicine - Subspecialty Farmacology PhD
- January 1993-December 1997 **Neurology Consultant**

Hospital Santa Maria (CHLN) (Portugal)

Neurology Residency

Sub-speciality: Movement / Neurodegenerative disorders

- 2008

Clinical Pharmacology Consultant

Ordem dos Médicos (Portuguese Medical Board) (Portugal)

Clinical Pharmacology

ADDITIONAL INFORMATION

Expertise

Clinical Neuropharmacology

Movement and Neurodegenerative disorders

Pharmacoepidemiology

Regulatory Science

Medical Ethics

Publications

Peer Review Journals

1. Sampaio C, Castro-Caldas A, Pinto L, Apolinario P, Rosa MM, Ferreira JJ. Tratamento das distonias focais e hemiespasmo facial com toxina botulinica tipo A. Revista Portuguesa de Neurologia 1992; 1, 4: 55-61.
2. Martins R, Simoes F, Garrett et al (Rosa MM Member of the PARJUPAR Study Group). Selegilina e/ou bromocriptina nos estadios iniciais da Doenca de Parkinson (Estudo Parjupar): justificacao, metodologia e resultados da 1ª analise interina. Revista Portuguesa de Neurologia 1993; 2, 4: 199-204.
3. Sampaio C, Branco MC, Rosa MM, Castro-Caldas A. A negative pharmacokinetic interaction between subcutaneous Apomorphine and Levodopa/Carbidopa (Sinemet). Clin drug Invest 9 (6): 363-366 (1995).
4. Perani D, Cappa SF, Schnur T, Tettamanti, Collina SM, Rosa MM, Fazio F. The Neural Correlates of Verb and Noun Processing - A PET Study. Brain 1999; 122, 2337-2344.
5. Costa J, Rosa MM, Ferreira JJ, Sampaio C, Vaz Carneiro A. [Cardiac effects of acute poisoning with tricyclic antidepressants: systematic review of the literature. Part I] Os efeitos cardiacos da intoxicacao aguda por antidepressivos triciclicos: revisao sistematica da literatura. Parte I Rev Port Cardiol 2001 Jun; 20(6): 671-8.
6. Costa J, de Oliveira EI, Rosa MM, Ferreira JJ, Sampaio C, Carneiro AV. [Cardiac effects of acute poisoning with tricyclic antidepressants: systematic review of the literature. Part II] Os efeitos cardiacos da intoxicacao aguda por antidepressivos triciclicos: revisao sistematica da literatura. Parte II Rev Port Cardiol 2001 Jul-Aug; 20(7-8): 765-72.
7. Costa J, Rosa MM, Ferreira JJ, Sampaio C, Vaz Carneiro A. [Cardiac effects of acute poisoning with tricyclic antidepressants: systematic review of the literature. Part III] Os efeitos cardiacos da intoxicacao aguda por antidepressivos triciclicos: revisao sistematica da literatura. Parte III Rev Port Cardiol 2001 Set; 20(9): 901-909.
8. Costa J, Rosa MM, Ferreira JJ, Sampaio C, Vaz Carneiro A. [Cardiac effects of acute poisoning with tricyclic antidepressants: systematic review of the literature. Part IV] Os efeitos cardiacos da intoxicacao aguda por antidepressivos triciclicos: revisao sistematica da literatura. Parte IV Rev Port Cardiol 2001 Out; 20(10): 1021-1030.
9. Perani D, Cappa SF, Tettamanti M, Rosa M, Scifo P, Miozzo A, Basso A, Fazio F. A fMRI study of word retrieval in aphasia. Brain Lang. 2003 Jun;85(3):357-68.
10. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of pramipexole as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord 2003;18:418-25.
11. Murat Emre, M.D., Dag Aarsland, M.D., Ph.D., Alberto Albanese, M.D., E. Jane Byrne, F.R.C.Psych., M.B., Ch.B., Gunther Deuschl, M.D., Peter P. De Deyn, M.D., Ph.D., Franck Durif, M.D., Ph.D., Jaime Kulisevsky, M.D., Ph.D., Teus van Laar, M.D., Ph.D., Andrew Lees, M.D., Werner Poewe, M.D., Alain Robillard, M.D., F.R.C.P.C., Mario M. Rosa, M.D., Erik Wolters, M.D., Ph.D., Peter Quarg, M.Sc., Sibel Tekin, M.D., and Roger Lane, M.D. Rivastigmine for Dementia Associated with Parkinson's Disease. N Engl J Med. 2004 Dec 9;351(24):2509-18.
12. Rascol, D J Brooks, E Melamed, W Oertel, W Poewe, F Stocchi, E Tolosa, for the LARGO study group*. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a

randomised, double-blind, parallel-group trial. *Lancet* 2005 12 Mar; 365: 947-54.

13. Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlief F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, Del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK. on behalf of the EMSA-SG. The European Multiple System Atrophy-Study Group (EMSA-SG). *J Neural Transm.* 2005 Dec;112(12):1677-1686.

14. Rascol, D J Brooks, E Melamed, W Oertel, W Poewe, F Stocchi, E Tolosa. for the LARGO study group (Rosa MM investigator of the LARGO study group). Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. *Lancet* 2005 12 Mar; 365: 947-54.

15. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J (Rosa MM as a Study Site investigator). TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol.* 2006 Dec;5(12):1013-20.

16. Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P et al (Rosa MM Member of the Parkinson-Control Study Group). The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. *Mov Disord* 2006;21:500-9.

17. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J (Rosa MM in PELMOPET Study Group). Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. *Mov Disord.* 2006 Mar;21(3):343-53.

18. Poewe W, Wolters E, Emre M, Onofrij M, Hsu C, Tekin S, Lane R; EXPRESS Investigators (Rosa MM EXPRESS Investigator). Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. *Mov Disord.* 2006 Apr;21(4):456-61.

19. Ferreira JJ, Couto M, Costa J, Coelho M, Rosa MM, Sampaio C., Botulinum toxin for the treatment of pain syndromes, *Acta Reumatol Port.* Jan-Mar 2006;31(1):49-62.

20. Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial (Rosa MM as a Study Site investigator). *Mov Disord* 2007;22(2):179-86.

21. Ferreira JJ, Guedes LC, Rosa MM, Coelho M, van Doeselaar M, Schweiger D et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. *Mov Disord* 2007;22(8):1194-201

22. Ferreira JJ, Silva JM, Freire R, Pignatelli J, Guedes LC, Feijo A, Rosa MM et al. Skin cancers and precancerous lesions in Parkinson's disease patients. *Mov Disord* 2007;22(10):1471-5.

23. Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januario C et al. Clinical Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson's disease. *Clinical Neuropharmacology* 2008;31(1):2-18.

24. Coelho M, Ferreira JJ, Rosa M, Sampaio C. Treatment options for non-motor symptoms in late-stage Parkinson's disease. *Expert Opin Pharmacother.* 2008 Mar;9(4):523-35

25. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium (Tazir M, Ysmail-Dahlouk F, Belarbi S, Hecham N, Barbosa E, Chien HF, Rieder CR, Jardim LB, Rogava E, Lesage S, Lohmann E, Vidailhet M, Bonnet AM, Agid Y, Pollak P, Tison F, Durif F, Broussolle E, Berg D, Hagenah J, Gosal D, Gibson M, Vanacore N, Berardelli A, Fabrini G, Fabrizio E, Meco G, Stocchi F, Dalla Libera A, De Mari M, Lamberti P, Cossu G, Pezzoli G, Zini M, Tesi S, Zecchinelli A, Sironi F, Antonini A, Mariani C, Sacilotto G, Meucci N, Canesi M, Di Fonzo A, Oostra B, Correia Guedes L, Rosa MM, Coelho M, Sampaio C, Gaig C, Lu CS, Wu-Chou YH, Quinn NP, Abou-Sleiman PM, Muqit MM, Khan NL, Gandhi S, Vaughan J, Payami H, Nutt JJ, Factor SA, Higgins DS, Farrer MJ, Hulihan M, Brown L, Mata IF, Samii A, Yearout D, Griffith A, Leis BC, Roberts JW.). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol.* 2008 Jul;7(7):583-90.

26. Gerald R, Coelho M, Rosa MM, Severino L, Castro J, de Carvalho M. Abnormal transcranial magnetic stimulation in a patient with presumed psychogenic paralysis. *J Neurol Neurosurg Psychiatry*. 2008 Dec;79(12):1412-3.
27. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group. (Easton JD, Kesselring J, Weinschenker BG, Laupacis A, Zarbin M, Calandra T, Temkin N, DiMarco J, Hudson LD, Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Radue EW, Antel J, Durcan L, Bar Or A, Duquette P, Bernier G, Freedman M, MacLean H, Costello F, O'Connor P, Gray TA, Hohol M, Devonshire V, Hashimoto S, Sorensen PS, Datta P, Faber-Rod JC, Frederiksen J, Knudsen S, Petrenaite V, Harno H, Farkkila M, Halavaara J, Elovaara I, Kuusisto H, Palmio J, Airas L, Kaasinen V, Laaksonen M, Vermersch P, Pelletier J, Feuillet L, Suchet L, Mauch E, Gunser C, Oberbeck K, Rieckmann P, Buttmann M, Klein M, Ghezzi A, Zaffaroni M, Baldini S, Mancardi G, Cioli F, Capello E, Comi G, Rodegher M, Radaelli M, Pozzilli C, Onesti E, Romano S, Czlonkowska A, Litwin T, Darda-Ledzion L, Kwiecinski H, Golebiowski M, Podlecka A, Nojszewska K, Cunha L, Sousa L, Matias F, Pedrosa R, Almeida M, Pena JE, de Sa J, Ferreira J, Rosa M, Arbizu T, Carmona O, Casado V, Montalban X, Tintore M, Pelayo R, Arroyo R, Bartolome M, De las Heras V, Casanova B, Bosca I, Fernandez O, Leon A, Romero F, Izquierdo G, Gamero M, Garcia JM, Kappos L, Kuhle J, Mehling M, Achtnichts L, Goebels N, Skulina C, Waskoenig J, Bates D, Nichols P, Radue EW, Bendfeldt K, Karlsson G, Burtin P, Zupal T.). Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. *Neurology*. 2009 Jan 6;72(1):73-9.
28. Mestre T, Ferreira JJ, Coelho M, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. *Cochrane Database Syst Rev*. 2009 Jul 8;(3):CD006456
29. Mestre T, Ferreira JJ, Coelho M, Rosa M, Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. *Cochrane Database Syst Rev*. 2009 Jul 8;(3):CD006455
30. Rosa, MM. Boas Praticas Clinicas (Good Clinical Practices). *Sinapse* 2009. 9 (1):51-55.
31. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarietka A; FIRST-STEP Study Group (Rosa MM Member of the FIRST-STEP Study Group). Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. *Mov Disord*. 2009 Mar 15;24(4):541-50.
32. Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA (Bachoud-Levi AC, Bentivoglio AR, Biunno I, Bonelli R, Burgunder JM, Dunnett SB, Ferreira J, Handley OJ, Heiberg A, Illmann T, Landwehrmeyer GB, Levey J, Nielsen JE, Paivarinta M, Roos RA, Rojo Sebastian A, Tabrizi SJ, Vandenberghe W, Verellen-Dumoulin C, Zaremba J, Uhrova T, Wahlstrom J, Schwenke C, Orth M, Illmann T, Wallner M, Barth K, Bascunana Garde M, Ros R, Ecker D, Handley OJ, Heinonen N, Held C, Laura M, Martinez Descals A, Mestre T, Monza D, Naji J, Orth M, Padiou H, Pro Koivisto S, Riialand A, Sasinkova P, Trigo Cubillo P, van Walsem M, Witjes-Ane MN, Zielonka D, Bonelli RM, Herranhof B, Hodl A, Koppitz M, Magnet M, Otti D, Painold A, Reisinger K, Flamez A, Morez V, de Raedt S, Ribai P, Verellen-Dumoulin C, Vandenberghe W, Van Reijnen D, Hasholt L, Hjermland LE, Jakobsen O, Norremolle A, Sorensen SA, Stokholm J, Peippo M, Sipponen M, Hiivola H, Martikainen K, Tuuha K, Kosinski CM, Probst D, Sass C, Schiefer J, Schlangen C, Werner CJ, Priller J, PruB H, Andrich J, Hoffmann R, Kraus P, Prehn C, Saft C, Salmen S, StraBburger K, Lange H, Hunger U, Lohle M, Schmidt S, Storch A, Wolz A, Wolz M, Lambeck J, Zucker B, Hidding U, Munchau A, Orth M, Stubbe L, Heinicke W, Longinus B, Moller JC, Rissling I, Peinemann A, Stadler M, Weindl A, Bohlen S, Reilmann R, Beuster A, Dose M, Leythaeuser G, Marquard R, Schrenk C, Schuierer M, Wiedemann A, Ecker D, Landwehrmeyer B, Lezius F, Trautmann S, Bertini E, Mechi C, Paganini M, Piacentini S, Romoli M, Sorbi S, Abbruzzese G, Bandettini di Poggio M, Ferrandes G, Mandes P, Marchese R, Albanese A, Di Donato S, Mariotti C, Soliveri P, Carlo R, Luigi DM, De michele G, Rinaldi C, Salvatore E, Tucci T, Ciarmiello A, Martino T, Simonelli M, Squitieri F, Bentivoglio AR, Fasano A, Frontali M, Guidubaldi A, Lalongo T, Jacopini G, Loria G, Piano C, Romano S, Soleti F, Spadaro M, Zinzi P, Heiberg A, van Walsem MR, Bjorgo K, Fannemel M, Gorrvel P, Retterstol L, Bjornevoll I, Sando SB, Sitek EJ, Slawek J, Soltan W, Rudzinska M, Szczudlik A, Wojcik M, Bryl A, Ciesielska A, Klimberg A, Kozubski W, Marcinkowski J, Sempolowicz PJ, Zielona D, Janik P, Kalbarczyk A, Kwiecinski H, Jamrozik Z, Antczak J, Rakowicz M, Richter P, Ryglewicz D, Zaremba J, Zdzienicka E, Costa C, Coelho M, Ferreira JJ, Mestre T, Rosa MM, Valadas A, Gago M, Garrett C, Guerra MR, Bas J, Calopa M, Barbera MA, Badenes D, Casas L, Arroyo SE, Vara JH, Krupinski J, Lopez J, Obdulia M, Ferrer PQ, Sebastian AR, Contreras SR, Carruesco GT, Cubo E, Mariscal N, Sanchez J, Barrero FJ, Morales B, Garcia-Ramos Garcia R, Pin Quiroga P, Villanueva C, Ruiz-Espiga PJ, Martinez A, Saiz Artiga MJ, Sanchez V, Bascunana M, Fatas M, Ribas GG, de Yébenes JG, Lopez Moreno JL, Schwarz C, Cubillo PT, Arques PN, Gorospe A, Legarda I,

Rodriguez MJ, Gaston I, Ramos-Arroyo MA, del Val JL, Martinez L, Burgunder JM, Romero I, Schupbach M, Zaugg SW, van Hout MS, van Vugt JP, de Weert AM, Bolwijn JJ, Dekker M, Leenders KL, van Oostrom JC, Bos R, Dumas E, Jurgens CK, Roos RA, Witjes-Ane MN, Matheson K, Rae D, Simpson S, Summers F, Ure A, Curtis A, Keylock J, Rickards H, Wright J, Barker RA, Fisher K, Goyder Goodman AO, Hill S, Kershaw A, Mason S, Paterson N, Raymond L, Bisson J, Busse M, Ellison-Rose L, Handley O, Naji J, Price K, Rosser A, Edwards M, De Sousa PA, Hughes T, McGill M, Pearson P, Porteous M, Zema A, Brockie P, Foster J, Johns N, McKenzie S, Thomas G, Burrows L, Fletcher A, Laver F, Silva M, Thomas A, Chu C, Hobson E, Jamieson S, Toscano J, Wild S, Yardumian P, Bourne C, Clayton C, Dipple H, Grant J, Gross D, Hallam C, Middleton J, Murch A, Andrews T, Dougherty A, Kavalier F, Golding C, Lashwood A, Robertson D, Ruddy D, Whaite A, Andrews T, Bruno S, Golding C, Henley S, O'Driscoll C, Patel A, Rosser E, Tabrizi S, Taylor R, Warner T, Wild E, Arran N, Craufurd D, Fullam R, Howard L, Huson S, Partington-Jones L, Ritchie N, Snowden J, Solom A, Stopford C, Thompson J, Westmoreland L, Nemeth AH, Siuda G, Bandmann O, Bradbury A, Fillingham K, Foustanos I, Quarrell O, Reynders H, Robertson L, Tidswell K.). Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. *Neurology*. 2009 Oct 20;73(16):1280-5.

33. Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C. Skin cancer and Parkinson's disease. *Mov Disord*. 2010 Jan 30;25(2):139-48.

34. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group (Easton JD, Kesselring J, Weinschenker BG, Laupacis A, Zarbin M, Calandra T, Temkin N, DiMarco J, Hudson LD, Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Radue EW, Antel J, Durcan L, Bar Or A, Duquette P, Bernier G, Freedman M, MacLean H, Costello F, O'Connor P, Gray TA, Hohol M, Devonshire V, Oger J, Hashimoto S, Sorensen PS, Datta P, Faber-Rod JC, Frederiksen J, Knudsen S, Petrenaitė V, Farkkila M, Harno H, Halavaara J, Elovaara I, Kuusisto H, Palmio J, Airas L, Kaasinen V, Laaksonen M, Vermersch P, Pelletier J, Feuillet L, Suchet L, Mauch E, Gunser C, Oberbeck K, Rieckmann P, Buttman M, Klein M, Ghezzi A, Zaffaroni M, Baldini S, Mancardi G, Cioli F, Capello E, Comi G, Rodegher M, Radaelli M, Pozzilli C, Onesti E, Romano S, Czlonkowska A, Litwin T, Darda-Ledzion L, Kwiecinski H, Golebiowski M, Podlecka A, Cunha L, Sousa L, Matias F, Pedrosa R, Almeida M, Pena JE, de Sa J, Ferreira J, Rosa M, Arbizu T, Carmona O, Casado V, Montalban X, Tintore M, Pelayo R, Arroyo R, Bartolome M, De las Heras V, Casanova B, Bosca I, Fernandez O, Leon A, Romero F, Izquierdo G, Gamero M, Garcia JM, Kappos L, Kuhle J, Mehling M, Achtnichts L, Goebels N, Skulina C, Waskoenig J, Bates D, Nichols P, Radue EW, Bendfeldt K, Karlsson G, de Vera A, Gruenbauer W.). Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. 2010 Feb;16(2):197-207.

35. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. *Parkinsonism Relat Disord*. 2010 May;16(4):237-42.

36. Coelho M, Marti MJ, Tolosa E, Ferreira JJ, Vallderiola F, Rosa M, Sampaio C. Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. *J Neurol*. 2010 Apr 257:1524-1532.

37. Rosa MM, Ferreira JJ, Coelho M, Freire R, Sampaio C. Prescribing patterns of antiparkinsonian agents in Europe. *Mov Disord*. 2010 Jun 15;25(8):1053-60.

38. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington's Disease Network. (Bonelli R, Herranhof B, Hodl A, Koppitz M, Magnet M, Otti D, Painold A, Reisinger K, Flamez A, Morez V, de Raedt S, Ribai P, Verellen-Dumoulin C, Vandenberghe W, van Reijen D, Hasholt L, Hjermind L, Jakobsen O, Norremolle A, Sorensen S, Stokholm J, Peippo M, Sipponen M, Hiivola H, Martikainen K, Tuuha K, Kosinski C, Probst D, Sass C, Schiefer J, Schlangen C, Werner C, Priller J, Pruss H, Andrich J, Hoffmann R, Kraus P, Prehn C, Saft C, Salmen S, Strassburger K, Lange H, Hunger U, Lohle M, Schmidt S, Storch A, Wolz A, Wolz M, Lammbeck J, Zucker B, Hidding U, Munchau A, Orth M, Stubbe L, Heinicke W, Orth M, Longinus B, Moller J, Rissling I, Peinemann A, Stadler M, Weindl A, Bohlen S, Lange H, Reilmann R, Beister A, Dose M, Leythaeuser G, Marquard R, Schrenk C, Schuierer M, Wiedemann A, Ecker D, Landwehrmeyer B, Lezius F, Trautmann S, Bertini E, Mechi C, Paganini M, Piacentini S, Romoli M, Sorbi S, Abbruzzese G, di Poggio M, Di Maria E, Ferrandes G, Mandich P, Marchese R, Albanese A, Di Donato S, Mariotti C, Soliveri P, Carlo R, Luigi D, De Michele G, Rinaldi C, Salvatore E, Tucci T, Ciarmiello A, Martino T, Simonelli M, Squitieri F, Bentivoglio A, Fasano A, Frontali M, Guidubaldi A, Ialongo T, Jacopini G, Loria G, Piano C, Romano S, Soleti F, Spadaro M, Zinzi P, Heiberg A, van Walsem M, Bjorgo K, Fannemel M, Lars Retterstol P, Bjornevoll I, Sando S, Sitek E, Slawek J, Soltan W, Boczarska-Jedynak M, Jasinska-Myga B, Opala G, Rudzinska M, Szczudlik A, Wojcik M, Banaszkiwicz K, Bryl A, Ciesielska A, Klimberg A, Kozubski W, Marcinkowski J, Sempolowicz P, Zielonka D, Janik P,

Kalbarczyk A, Kwiecinski H, Jamrozik Z, Antczak J, Witkowski G, Rakowicz M, Richter P, Ryglewicz D, Zaremba J, Zdzienicka E, Costa C, Coelho M, Ferreira J, Mestre T, Rosa M, Valadas A, Gago M, Garrett C, Guerra M, Bas J, Calopa M, Barbera M, Badenes D, Casas L, Arroyo S, Vara J, Krupinski J, Lopez J, Obdulia M, Ferrer P, Sebastian A, Contreras S, Carruesco G, Cubo E, Mariscal N, Sanchez J, Barrero F, Morales B, Lopez-Sendon Moreno J, Garcia RR, Quiroga P, Villanueva C, Ruiz-Espiga PJ, Martinez A, Artiga MS, Sanchez V, Bascunana M, Fatas M, Ribas G, de Yebenes J, Lopez Moreno J, Schwarz C, Cubillo P, Arques P, Gorospe A, Legarda I, Torres Rodriguez M, Gaston I, Ramos-Arroyo MA, Del Val JL, Martinez L, Burgunder JM, Romero I, Schupbach M, Zaugg SW, van Hout MS, van Vugt JP, de Weert AM, Bolwijn JJ, Dekker M, Leenders KL, van Oostrom JC, Bos R, Dumas E, Jurgens CK, Roos RA, Witjes-Ane MN, Matheson K, Rae D, Simpson S, Summers F, Ure A, Curtis A, Keylock J, Rickards H, Wright J, Barker R, Fisher K, Goodman AG, Hill S, Kershaw A, Mason S, Paterson N, Raymond L, Bisson J, Busse M, Ellison-Rose L, Handley O, Dunnett S, Naji J, Price K, Rosser A, Edwards M, De Sousa P, Hughes T, McGill M, Pearson P, Porteous M, Zema A, Brockie P, Foster J, Johns N, McKenzie S, Thomas G, Burrows L, Fletcher A, Laver F, Silva M, Thomson A, Chu C, Hobson E, Jamieson S, Toscano J, Wild S, Yardumian P, Bourne C, Clayton C, Dipple H, Grant J, Gross D, Hallam C, Middleton J, Murch A, Andrews T, Dougherty A, Kavalier F, Golding C, Lashwood A, Robertson D, Ruddy D, Whaite A, Andrews T, Bruno S, Golding C, Henley S, Novak M, O'Driscoll C, Patel A, Rosser E, Tabrizi S, Taylor R, Warner T, Wild E, Arran N, Craufurd D, Fullam R, Howard L, Huson S, Partington-Jones L, Ritchie N, Snowden J, Solom A, Stopford C, Thompson J, Westmoreland L, Nemeth A, Siuda G, Bandmann O, Bradbury A, Fillingham K, Foustanos I, Quarrell O, Reynders H, Robertson L, Tidswell K.). Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. *PLoS Curr.* 2010 Sep 28 [revised 2011 Apr 13];2:RRN1184.

39. Reese JP, Winter Y, Rosa MM, Rodrigues E Silva AM, von Campenhausen S, Freire R, Mateus C, Balzer-Geldsetzer M, Botzel K, Oertel WH, Dodel R, Sampaio C. [Health-economic burden of Parkinson's disease in Portugal: a cohort study]. *Rev Neurol.* 2011 Mar 1;52(5):264-74.

40. Martins M, Rosa A, Guedes LC, Fonseca BV, Gotovac K, Violante S, Mestre T, Coelho M, Rosa MM, Martin ER, Vance JM, Outeiro TF, Wang L, Borovecki F, Ferreira JJ, Oliveira SA. Convergence of miRNA expression profiling, -synuclein interactome and GWAS in Parkinson's disease. *PLoS One.* 2011;6(10):e25443.

41. Reimao S, Morgado C, Neto L, Ferreira J, Coelho M, Rosa M, Campos J. Diffusion Tensor Imaging in Movement Disorders: Review of Major Patterns and Correlation with Normal Brainstem/cerebellar White Matter. *Neuroradiol J.* 2011 May 15;24(2):177-86.

42. Lobo PP, Coelho M, Gerales R, Santos C, Gracio M, Rosa MM, Antunes JL. Myeloradiculopathy associated to *Schistosoma mansoni*. *BMJ Case Rep.* 2011 Aug 11;2011.

43. Teodoro T, Pires D, Rosa MM, Coelho M, Sampaio C, Ferreira JJ. Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials? *Mov Disord.* 2011 Aug 15;26(10):1966-7

44. Saft C, Epplen JT, Wiczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Arning L. (Barth K, Bascunana Garde M, Bos R, Ecker D, Handley O, Heinonen N, Held C, Laura M, Martinez Descals A, Mestre T, Monza D, Naji J, Orth M, Padiou H, Pro Koivisto S, Riialand A, Sasinkova P, Trigo Cubillo P, van Walsem M, Witjes-Ane MN, Zielonka D, Bonelli R, Herranhof B, Hodl A, Kapfhammer HP, Koppitz M, Magnet M, Otti D, Painold A, Reisinge K, Brugger F, Hepperger C, Hotter A, Mahlknecht P, Nocker M, Seppi K, Wenning G, Ribai P, Verellen-Dumoulin C, Klempir J, Kucharik M, Roth J, Hasholt L, Hjermind L, Jakobsen O, Nielsen J, Norremolle A, Sorensen S, Stokholm J, Hiivola H, Martikainen K, Tuuha K, Kosinski C, Probst D, Sass C, Schiefer J, Schlangen C, Werner C, Lange H, Lohle M, Storch A, Wolz A, Wolz M, Lambeck J, Zucker B, Munchau A, Stubbe L, Zittel S, Heinicke W, Longinus B, Peinemann A, Stadler M, Weindl A, Bohlen S, Lange H, Reilmann R, Beister A, Dose M, Hammer K, Leythaeuser G, Marquard R, Raab T, Schrenk C, Schuierer M, Wiedemann A, Beister A, Dose M, Hammer K, Leythaeuser G, Marquard R, Raab T, Schrenk C, Schuierer M, Wiedemann A, Ecker D, Eschenbach C, Landwehrmeyer B, Lezius F, Orth M, Trautmann S, Cormio C, Difruscolo O, de Tommaso M, Sciricchio V, Serpino C, Bertini E, Mechi C, Paganini M, Piacentini S, Romoli M, Sorbi S, Abbruzzese G, Di Maria E, Bandettini di Poggio Giovanna Ferrandes M, Mandich P, Marchese R, Albanese A, Di Donato S, Mariotti C, Soliveri P, Gellera C, Monza D, Tomasello C, Nanetti L, Luigi D, De Michele G, Rinaldi C, Russo C, Salvatore E, Tucci T, Squitieri F, Martino T, Orobello S, Alberti S, De Gregorio F, Codella V, De Nicola N, Maglione V, Bentivoglio A, Fasano A, Frontali M, Guidubaldi A, Ialongo T, Jacopini G, Loria G, Piano C, Romano S, Soleti F, Spadaro M, Zinzi P, Heiberg A, van Walsem M, Bjorgo K, Fannemel M, Gorrvell P, Retterstol L, Bjornevoll I, Botne Sando S, Slawek J, Soltan W, Sitek E, Boczarska-Jedynak M, Jasinska-Myga B, Opala G, Szczudlik A, Rudzinska M, Wojcik M,

Banaszkiewicz K, Krawczyk M, Zielonka D, Marcinkowski J, Ciesielska A, Sempolowicz J, Bryl A, Klimberg A, Janik P, Kalbarczyk A, Kwiecinski H, Jamrozik Z, Witkowski G, Ryglewicz D, Antczak J, Rakowicz M, Jachinska K, Zdzienicka E, Richter P, Zaremba J, Coelho M, Ferreira J, Mestre T, Rosa M, Valadas A, Gago M, Garrett C, Guerra M, Barrero F, Morales B, Lopez-Sendon Moreno J, Cubo E, Mariscal N, Sanchez J, Garcia R, Villanueva C, Pin Quiroga P, Bascunana M, Trigo Cubillo P, Fataas M, Luis Lopez Moreno J, Garcia Ribas G, Schwarz C, de Yebenes JG, Jose Saiz Artiga M, Martinez-Descals A, Garcia Ruiz P, Sanchez V, Fortuna Alcaraz L, Fuensanta Noguera Perea M, Martirio Antequera Torres M, Vivancos Moreau L, Rojo Sebastian A, Aguilar Barbera M, Badenes Guia D, Casas Hernanz L, Tome Carruesco G, Suarez San Martin E, Lopez Catena J, Bas J, Calopa M, Busquets N, Navas Arques P, Gorospe A, Legarda I, Jose Torres Rodriguez M, Vives B, Carrillo F, Mir P, Jose Lama Suarez M, Loutfi G, Stattin EL, Westman L, Wikstrom B, Palhagen S, Bjornsson E, Burgunder JM, Romero I, Schupbach M, Weber Zaugg S, van Hout M, van Vugt J, Marit de Weert A, Bolwijn JJ, Dekker M, Leenders KL, van Oostrom JC, Bos R, Dumas E, Jurgens C, van den Bogaard SA, Roos R, Witjes-Ane MN, Kremer B, Verstappen CC, de Souza J, Rickards H, Wright J, Barker R, Fisher K, Goyder Goodman A, Hill S, Kershaw A, Mason S, Paterson N, Raymond L, Bisson J, Busse M, Ellison-Rose L, Handley O, Hunt S, Naji J, Price K, Rosser A, Dunnett S, Edwards M, De Sousa P, Hughes T, McGill M, Pearson P, Porteous M, Smith P, Zeman A, Lambord N, Rankin J, Burrows L, Fletcher A, Laver F, Silva M, Thomson A, Andrews T, Dougherty A, Kavalier F, Golding C, Lashwood A, Robertson D, Ruddy D, Whaite A, Patton M, Patterson M, Bourne C, Clayton C, Dipple H, Clapton J, Grant J, Gross D, Hallam C, Middleton J, Murch A, Patino D, Andrews T, Bruno S, Chu E, Doherty K, Lahiri N, Novak M, Patel A, Tabrizi S, Taylor R, Warner T, Wild E, Arran N, Craufurd D, Fullam R, Howard L, Huson S, Partington-Jones L, Verstraelen N, Snowden J, Sollom A, Stopford C, Thompson J, Westmoreland L, Nemeth A, Siuda G, Bandmann O, Bradbury A, Fillingham K, Foustanos I, Tidswell K, Quarrell O.). NMDA receptor gene variations as modifiers in Huntington disease: a replication study. *PLoS Curr.* 2011 Oct 4;3:RRN1247.

45. Valadas A, Coelho M, Mestre T, Guedes LC, Finisterra M, Noronha A, Rosa MM, Sampaio C, Ferreira JJ. What motivates Parkinson's disease patients to enter clinical trials? *Parkinsonism Relat Disord.* 2011 Nov;17(9):667-71.

46. Teodoro T, Neutel D, Lobo P, Geraldo AF, Conceicao I, Rosa MM, Albuquerque L, Ferreira JJ. Recovery after copper-deficiency myeloneuropathy in Wilson's disease. *J Neurol.* 2013 Jul;260(7):1917-8.

47. Pita Lobo P, Coelho M, Mestre TA, Rosa MM, Ferreira JJ. Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism. *Mov Disord.* 2013 Aug;28(9):1212-4.

48. Zhang L, Quadri M, Guedes LC, Coelho M, Valadas A, Mestre T, Lobo PP, Rosa MM, Simons E, Oostra BA, Ferreira JJ, Bonifati V. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants. *Parkinsonism Relat Disord.* 2013 Oct;19(10):897-900.

49. Albuquerque L, Coelho M, Martins M, Guedes LC, Rosa MM, Ferreira JJ, Cattoni MB, Carvalho H, Ferreira AG, Martins IP. STN-DBS does not change emotion recognition in advanced Parkinson's disease. *Parkinsonism Relat Disord.* 2014 Feb;20(2):166-9.

50. Fabbri M, Guedes LC, Coelho M, Simao D, Abreu D, Rosa MM, Silveira-Moriyama L, Ferreira JJ. Subthalamic deep brain stimulation effects on odor identification in Parkinson's disease. *Eur J Neurol.* 2015 Jan;22(1):207-10.

51. Coelho M, Marti MJ, Sampaio C, Ferreira JJ, Valldeoriola F, Rosa MM, Tolosa E. Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson's disease: the Barcelona-Lisbon cohort. *Eur J Neurol.* 2015 Feb;22(2):305-12.

52. Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. *Lancet Neurol.* 2015 Feb;14(2):145-52.

53. Reimao S, Pita Lobo P, Neutel D, Guedes LC, Coelho M, Rosa MM, Ferreira J, Abreu D, Goncalves N, Morgado C, Nunes RG, Campos J, Ferreira JJ. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. *J Parkinsons Dis.* 2015;5(3):561-7.

54. Reimao S, Pita Lobo P, Neutel D, Correia Guedes L, Coelho M, Rosa MM, Ferreira J, Abreu D, Goncalves N, Morgado C, Nunes RG, Campos J, Ferreira JJ. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. *Eur J Neurol.* 2015 Mar;22(3):540-6.

55. Morgado J, Reimao S, Coelho M, Rosa, MM, Ferreira JJ, Correia Guedes L. Eye of the Tiger Sign and Very Late Onset in Dentatorubral-Pallidoluysian Atrophy. *Movement Disorders Clinical Practice* 2015; 2(3), 313-315.
56. Rodrigues IT, Ferreira JJ, Coelho M, Rosa MM, Castro-Caldas A. Action verbal fluency in Parkinson's patients. *Arq Neuropsiquiatr*. 2015 Jun;73(6):520-5.
57. Reimao S, Pita Lobo P, Neutel D, Guedes LC, Coelho M, Rosa MM, Azevedo P, Ferreira J, Abreu D, Goncalves N, Nunes RG, Campos J, Ferreira JJ. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. *Mov Disord*. 2015 Jun;30(7):953-9.
58. Teodoro T, Nzwalo H, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ. Suicidal behaviors are very rare in antiparkinsonian drug trials. *Parkinsonism Relat Disord*. 2015 Aug;21(8):1008-9.
59. Morgado, J., Reimao, S., Coelho, M., Rosa, M. M., Ferreira, J. J. and Correia Guedes, L. Eye of the Tiger Sign and Very Late Onset in Dentatorubral-Pallidoluysian Atrophy. *Mov Disorders Clinical Practice*. 2015; 2: 313-315. doi: 10.1002/mdc3.12179
60. Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. *Neurodegener Dis Manag*. 2015 Dec;5(6):481-96.
61. Albuquerque L, Martins M, Coelho M, Guedes L, Ferreira JJ, Rosa M, Martins IP. Advanced Parkinson disease patients have impairment in prosody processing. *Journal of clinical and experimental neuropsychology*, 2016; 38(2), 208-216.
62. Fabbri Margherita, Coelho Miguel, Abreu Daisy, Correia Guedes Leonor, Rosa Mario-M., Costa Nilza, Antonini Angelo, Ferreira Joaquim J. Do patients with late-stage Parkinson's disease still respond to levodopa? *Parkinsonism Relat Disord*. 2016 Feb 26. Doi: 10.1016/j.parkreldis.2016.02.021.
63. Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, Rascol O. Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. *Frontiers in Neurology*, 2016 Mar 8;7:27.
64. Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martinez-Descalls A, Calvo S, Gil-Polo C; European HD Network. Clinical manifestations of intermediate allele carriers in Huntington disease. *Neurology*. 2016 Aug 9;87(6):571-8. Epub 2016 Jul 8.
65. Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Goncalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltenyi G, Borovecki F, Soreq H, Ferreira JJ, F Outeiro T. Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. *PLoS One*. 2016 Jun 20;11(6):e0157852.
66. Fabbri M, Rosa MM, Ferreira JJ. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease. *Neurodegener Dis Manag*. 2016 Oct;6(5):349-62.
67. Aartsma-Rus A, Balabanov P, Binetti L, Haas M, Haberkamp M, Mitchell J, Rosa MM, Muntoni F, Finkel R, Mercuri E. Stakeholder collaboration for spinal muscular atrophy therapy development. *Lancet Neurol*. 2017 Apr;16(4):264.
68. Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM, Abreu D, Costa N, Godinho C, Antonini A, Ferreira JJ. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. *Parkinsonism Relat Disord*. 2017 Jun;39:37-43.
69. Coelho M, Abreu D, Correia-Guedes L, Lobo PP, Fabbri M, Godinho C, Domingos J, Albuquerque L, Freitas V, Pereira JM, Cattoni B, Carvalho H, Reimao S, Rosa MM, Ferreira AG, Ferreira JJ. Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS. *J Parkinsons Dis*. 2017;7(2):255-261.
70. Fabbri M, Coelho M, Guedes LC, Chendo I, Sousa C, Rosa MM, Abreu D, Costa N, Godinho C, Antonini A, Ferreira JJ. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. *Parkinsonism Relat Disord*. 2017 Jun;39:37-43.
71. Fabbri M, Reimao S, Carvalho M, Nunes RG, Abreu D, Guedes LC, Bouca R, Lobo PP, Godinho C, Coelho M, Goncalves NC, Rosa MM, Antonini A, Ferreira JJ. Substantia Nigra Neuromelanin as na Imaging Biomarker of Disease Progression in Parkinson's Disease. *J Parkinsons Dis*. 2017;7(3):491-501.
72. Fabbri M, Coelho M, Guedes LC, Rosa MM, Abreu D, Goncalves N, Antonini A, Ferreira JJ. Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. *Parkinsonism Relat Disord*. 2017 Aug;41:113-117
73. Fabbri M, Guimaraes I, Cardoso R, Coelho M, Guedes LC, Rosa MM, Godinho C, Abreu D, Goncalves N, Antonini A, Ferreira JJ. Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. *Front Neurol*. 2017 Aug 22;8:432

74. Correia Guedes L, Reimao S, Paulino P, Nunes RG, Bouca-Machado R, Abreu D, Goncalves N, Soares T, Fabbri M, Godinho C, Pita Lobo P, Neutel D, Quadri M, Coelho M, Rosa MM, Campos J, Outeiro TF, Sampaio C, Bonifati V, Ferreira JJ. Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease. *Mov Disord*. 2017 Sep;32(9):1331-1333
75. Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Goncalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltenyi G, Borovecki F, Soreq H, Ferreira JJ, Outeiro TF. Correction: Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. *PLoS One*. 2017 Dec 28;12(12):e0190552
76. Vicente Miranda H, Cassio R, Correia-Guedes L, Gomes MA, Chegao A, Miranda E, Soares T, Coelho M, Rosa MM, Ferreira JJ, Outeiro TF. Posttranslational modifications of blood-derived alphasynuclein as biochemical markers for Parkinson's disease. *Sci Rep*. 2017 Oct 20;7(1):13713.
77. Caldeira D, Rodrigues R, Abreu D, Anes AM, Rosa MM, Ferreira JJ. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. *Expert Opin Drug Saf*. 2018 Apr;17(4):339-345.
78. Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? *J Neurol Neurosurg Psychiatry*. 2018 Aug;89(8):844-850.
79. Blauwendraat C, Reed X, Kia DA, Gan-Or Z, Lesage S, Pihlstrom L, Guerreiro R, Gibbs JR, Sabir M, Ahmed S, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Hernandez DG, Chung SJ, Goldwurm S, Toft M, Schulte C, Bras J, Wood NW, Brice A, Morris HR, Scholz SW, Nalls MA, Singleton AB, Cookson MR; COURAGE-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease) Consortium, the French Parkinson's Disease Consortium, and the International Parkinson's Disease Genomics Consortium (IPDGC). Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. *JAMA Neurol*. 2018 Nov 1;75(11):1416-1422. doi: 10.1001/jamaneurol.2018.1885.
80. Fabbri M, Rosa MM, Ferreira JJ. Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach. *Drugs Aging*. 2018 Dec;35(12):1041-1054. doi: 10.1007/s40266-018-0599-2.
81. Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Godinho C, Cardoso R, Guimaraes I, Antonini A, Zibetti M, Lopiano L, Ferreira JJ. Dysphagia predicts poor outcome in late-stage Parkinson's disease. *Parkinsonism Relat Disord*. 2019 Jul;64:73-81. doi:10.1016/j.parkreldis.2019.02.043.
82. Haberkamp M, Moseley J, Athanasiou D, de Andres-Trelles F, Elferink A, Rosa MM, Magrelli A.. European regulators' views on a wearable-derived performance measurement of Ambulation for Duchenne Muscular Disease regulatory trials. *Neuromuscul Disord*. 2019 Jul;29(7):514-516. doi: 10.1016/j.nmd.2019.06.003. Epub 2019 Jun 7.
83. Cerreta F, European Medicines Agency Geriatric Expert Group. New harmonized considerations. on the evaluation instruments for baseline characterization of frailty in the European Union. *Br J Clin Pharmacol*. 2019;1-3. <https://doi.org/10.1111/bcp.14044>
84. Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, Costa J, Ferreira J. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. *J Vasc Surg*. 2020 Jan;71(1):318-327. doi: 10.1016/j.jvs.2019.06.217. Epub 2019 Oct 30.
85. Mainoli B, Carvalho Dias M, Canhao P, Rosa MM. Suspected adverse reaction to compounded preparations prescribed for weight loss: two cases of cerebral venous thrombosis. *BMJ Case Rep*. 2020 Mar 31;13(3):e233746. doi: 10.1136/bcr-2019-233746.
86. Simoes RM, Castro Caldas A, Grilo J, Correia D, Guerreiro C, Pita Lobo P, Valadas A, Fabbri M, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ, Reimao S. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. *BMC Neurol*. 2020 Nov 27;20(1):432. doi: 10.1186/s12883-020-02007-5.
87. Gao D, David C, Rosa MM, Costa J, Pinto FJ, Caldeira D. The risk of mortality associated with opioid use in patients with acute heart failure: systematic review and meta-analysis. *J Cardiovasc Pharmacol*. 2020 Nov 17. doi: 10.1097/FJC.0000000000000954. Online ahead of print.
88. Fernandes N, Prada L, Rosa MM, Ferreira JJ, Costa J, Pinto FJ, Caldeira D. The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. *Clin Res Cardiol*. 2020 Jul 2. doi: 10.1007/s00392-020-01697-8. Online ahead of print.

89. Oliveira SR, Dionisio PA, Correia Guedes L, Goncalves N, Coelho M, Rosa MM, Amaral JD, Ferreira JJ, Rodrigues CMP. Circulating Inflammatory miRNAs Associated with Parkinson's Disease Pathophysiology. *Biomolecules*. 2020 Jun 23;10(6):945. doi: 10.3390/biom10060945. PMID: 32585840
90. Bouca-Machado R, Goncalves N, Lousada I, Patriarca MA, Costa P, Nunes R, Dias S, Caldas AC, Valadas A, Lobo PP, Guedes LC, Rosa MM, Coelho M, Ferreira JJ. Patients and Health Professional's Perspective of Functional Mobility in Parkinson's Disease. *Front Neurol*. 2020 Oct 27;11:575811. doi: 10.3389/fneur.2020.575811. eCollection 2020. PMID: 33193027
91. Lindeza P, Rodrigues M, Costa J, Guerreiro M, Rosa MM. Impact of dementia on informal care: a systematic review of family caregivers' perceptions. *BMJ Support Palliat Care*. 2020 Oct 14;bmjspcare-2020-002242. doi: 10.1136/bmjspcare-2020-002242.
92. Simoes, R.M., Castro Caldas, A., Grilo, J. et al. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. *BMC Neurol* 20, 432 (2020). <https://doi.org/10.1186/s12883-020-02007-5>
93. Reginster JY, Beudart C, Al-Daghri N, Avouac B, Bauer J, Bere N, Bruyere O, Cerreta F, Cesari M, Rosa MM, Cooper C, Cruz Jentoft AJ, Dennison E, Geerinck A, Gielen E, Landi F, Laslop A, Maggi S, Prieto Yerro MC, Rizzoli R, Sundseth H, Sieber C, Trombetti A, Vellas B, Veronese N, Visser M, Vlaskovska M, Fielding RA. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. *Aging Clin Exp Res* 33, 3-17 (2021). <https://doi.org/10.1007/s40520-020-01663-4>
94. Fernandes, N., Prada, L., Rosa, M.M. et al. The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. *Clin Res Cardiol* 110, 183-193 (2021). <https://doi.org/10.1007/s00392-020-01697-8>
95. Gao, D., David, C., Rosa, MM., Costa, J., Pinto, F.J., Caldeira, D. The Risk of Mortality Associated With Opioid Use in Patients With Acute Heart Failure: Systematic Review and Meta-analysis. *Journal of Cardiovascular Pharmacology*: February 2021 - Volume 77 - Issue 2 - p 123-129
doi: 10.1097/FJC.0000000000000954
96. Oliveira SR, Dionisio PA, Gaspar MM, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ, Amaral JD and Rodrigues CMP (2021) miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson's Disease. *Front. Cell Dev. Biol.* 9:661461. doi: 10.3389/fcell.2021.661461
97. Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML, Cavalier E, Hadji P, Halbout P, Harvey NC, Hilgsmann M, Javaid MK, Kanis JA, Kaufman JM, Lamy O, Matijevic R, Perez AD, Radermecker RP, Rosa MM, Thomas T, Thomasius F, Vlaskovska M, Rizzoli R, Cooper C. Management of patients at very high risk of osteoporotic fractures through sequential treatments. *Aging Clin Exp Res*. 2022 Mar 24. doi: 10.1007/s40520-022-02100-4. Online ahead of print. PMID: 35332506
98. Trombetti A, Al-Daghri N, Brandi ML, Cannata-Andia JB, Cavalier E, Chandran M, Chaussain C, Cipullo L, Cooper C, Haffner D, Harvengt P, Harvey NC, Javaid MK, Jiwa F, Kanis JA, Laslop A, Laurent MR, Linglart A, Marques A, Mindler GT, Minisola S, Yerro MCP, Rosa MM, Seefried L, Vlaskovska M, Zanchetta MB, Rizzoli R. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. *R. Nat Rev Endocrinol*. 2022 Apr 28. doi: 10.1038/s41574-022-00662-x. Online ahead of print. PMID: 35484227

Book Chapters

1. Ferreira JJ & Rosa MM. Doencas do Movimento. In J Ferro (Ed) "Terapeutica Neurologica", Lidel, 2001.
2. Ferreira JJ & Rosa MM. Doencas do Movimento. In J Ferro, Pedro Ponce et al (ed) "Manual de Terapeutica Medica", Vol 2, 33-52, Lidel, 2002.
3. Rosa MM, Guedes LC, Flutuacoes Motoras e Discinesias, Levy A, Ferreira J (Eds). In Doenca de Parkinson - Manual Pratico. Lidel - edicoes tecnicas, Lisboa 2003: pg 211-223.
4. Rosa MM, Anes AM, Medicamentos Causadores de Sintomas Parkinsonicos, Levy A, Ferreira J (eds). In Doenca de Parkinson - Manual Pratico. Lidel - edicoes tecnicas, Lisboa 2003: pg 287-275.
5. Rosa, MM. Reaccoes Adversas Neuropsiquiatricas, Vasco A. Maria et al (Eds). In Farmacovigilancia em Portugal - INFARMED, Lisboa 2003: pg 303-322.

6. Coelho MH, Ferreira JJ, Rosa MM. Doenças do Movimento, In Neurologia, Principios, diagnostico e Tratamento, capitulo VIII, Ferro J, Pimentel J (Eds). Lidel, 2006 2ª Ed, pg 135-168.
7. Guedes LC, Rosa MM. Flutuacoes motoras e discinesias. In Doenca de Parkinson - Manual Pratico. Ferreira JJ Coord. Lidel, Lisboa 2013: 238-253.
8. Anes AM, Rosa MM. Medicamentos causadores de sintomas Parkinsonianos. In Doenca de Parkinson - Manual Pratico. Ferreira JJ Coord. Lidel, 2ª Ed. Lisboa 2013: 340-345.
9. Ferreira JJ, Rosa MM, Coelho MH. Doenças do Movimento, In Neurologia fundamental, Principios, diagnostico e Tratamento, capitulo IX, Ferro J, Pimentel J (Eds). Lidel, 2013, pg 159-188.
10. Rosa MM, Dias T. Commonly used endocrine drugs. In Handbook of Clinical Neurology - Neurologic aspects of Systemic Diseases. Aminoff MJ, Boller F, Swaab D (Eds). 2014;120:809-24.
11. Rosa MM, Lobo Antunes J. Mecanismos de aprovacao, comercializacao e vigilancia do medicamento no espaco europeu. In Terapeutica Medicamentosa e suas bases farmacologicas - Manual de Farmacologia e Farmacoterapia. Guimaraes S, Moura D, Soares da Silva P, Eds. Porto Editora, 6ª Ed, Porto, 2014, pg 958-964.
12. Rosa MM, Anes AM. Drug-induced movement disorders. In Cristian Falup-Pecurariu, Joaquim Ferreira, Pablo Martinez-Martin, K Ray Chaudhuri, eds. Movement Disorders curricula. Springer, 2016
13. Mario Miguel Rosa, A. Marta Anes. 3.8 - Unidade de Farmacovigilancia de Lisboa. In Farmacovigilancia em Portugal: 25 anos. Sofia de Oliveira Martins Ed. INFARMED - Autoridade Nacional do Medicamento e Produtos de Saude, I. P. 131-137, 2019
14. Mario Miguel Rosa. 7.6 - Reacoes Adversas Neuropsiquiatricas. In Farmacovigilancia em Portugal: 25 anos. Sofia de Oliveira Martins Ed. INFARMED - Autoridade Nacional do Medicamento e Produtos de Saude, I. P. 461-479, 2019

Projects

- "Research Design and Data Analysis in Support of Clinical Trial Design and Clinical Research Projects" Local PI: Joaquim Ferreira. CHDI Foundation Project 2011-
- "Enroll-HD study - A Prospective Registry Study in a Global Huntington's Disease Cohort". Instituto de Medicina Molecular Joao Lobo Antunes, Lisbon, Portugal; Department of Neuroscience and Mental Health, Neurology Department, Hospital de Santa Maria, CHULN, Lisbon, Portugal. Local PI: Joaquim Ferreira. CHDI Foundation Project 2014-
- "Genetic susceptibility factors in Parkinson's disease": Department of Neuroscience and mental Health, Neurology Department, Hospital de Santa Maria, CHULN, Lisbon, Portugal; Erasmus Medical Centre, Rotterdam, Netherlands. PI: Prof Joaquim Ferreira, Prof Vincenzo Bonifati. 2011-
- "LRRK2 International Parkinson's disease program: an international, multicenter, epidemiological observational Study" : Instituto de Medicina Molecular Joao Lobo Antunes, Lisbon, Portugal; Department of Neuroscience and Mental Health, Neurology Department, Hospital de Santa Maria, CHULN, Lisbon, Portugal. Local PI: Joaquim Ferreira. PI: Christine Klein, University Luebeck, Germany 2016-
- "Michael J Fox Foundation (MJFF) Global Genetic Parkinson's Disease Study Group": Instituto de Medicina Molecular Joao Lobo Antunes, Lisbon, Portugal; Department of Neuroscience and Mental Health, Neurology Department, Hospital de Santa Maria, CHULN, Lisbon, Portugal. Local PI: Joaquim Ferreira. PI: Christine Klein, University Luebeck, Germany 2016-
- "Alliance to Identify LRRK2 Modifiers of Age of Onset with Family-based Whole Genome Analysis (WGA) and Validate them with Induced Pluripotent Stem Cell (iPSC) Models of LRRK2 PD". Instituto de Medicina Molecular Joao Lobo Antunes, Lisbon, Portugal; Gladstone Institute of Neurological Disease, San Francisco, EUA; PI: Prof Joaquim Ferreira; Internacional PI: Professor Steven Finkbeiner. 2016-
- "Genetic modifiers of age of onset of PD and penetrance among LRRK2 mutation carriers". Instituto de Medicina Molecular Joao Lobo Antunes, Lisbon, Portugal; Department of Medical and Molecular Genetics, Indiana University, EUA. PI Prof Joaquim Ferreira. International PI: Professor Tatiana Foroud.
- "Movement Disorders Biobanc of the Instituto de Medicina Molecular". Department of Neuroscience and Mental Health, Neurology Department, Hospital de Santa Maria, CHULN, Lisbon, Portugal; Instituto de Medicina Molecular Joao Lobo Antunes, Lisbon, Portugal. PI: Leonor Correia Guedes Clasp Consortium. Care for late parkinsonism. An European multicentre study. IP: Anette Schrag; IP local: Joaquim J Ferreira. EU Joint Programme for Neurodegenerative Disease Research (JPND). (Abril 2014 -).

Memberships Member of Conselho de Etica (Ethics Council) da Fundacao Champalimaud, Lisboa 2012, ongoing
Member (Present Chair) of Comissao de Etica para a Saude (Ethics Committee) do Campus Neurologico Senior (CNS), Torres Vedras 2016, ongoing
Member of Comissao de Etica para a Investigacao com Seres Humanos (Ethics Committee for Research in Humans) of Faculdade de Farmacia da Universidade de Lisboa (FFUL) 2018, ongoing
Member of the Joint Ethics Committee Centro Hospitalar Lisboa Norte - Faculdade de Medicina da Universidade de Lisboa 2004-2020
Movement Disorders Society (Past Member of the Education Committee - European Section 2009-2013)
European Academy of Neurology (Toxicology Board)
Sociedade Portuguesa de Neurologia (Portuguese Neurological Society)
Sociedade Portuguesa de Doencas do Movimento (Portuguese Movement Disorders Society)

Other Relevant Information Journal reviewer for International and National Journals (BMJ Case Reports, Frontiers - Neurology, Sinapse, Am J Clin Pharm Therap)